Faruqi and Faruqui, LLP Logo
Share this page

Alnylam Pharmaceuticals, Inc. (ALNY)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Alnylam stock or options between February 15, 2018 and September 12, 2018 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Alnylam securities between February 15, 2018 and September 12, 2018 (the “Class Period”).  The case, Hull Leavitt v. Alnylam Pharmaceuticals, Inc. et al, No. 1:18-cv-08845 was filed on September 26, 2018.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose and/or misleading investors as to the efficacy and safety of its Onpattro (patisiran) lipid complex injection.

Specifically, on September 12, 2018, Nomura/Instinet analyst Christopher Marai issued a report that conveyed to the market the full significance of the Onpattro review document released by the Food and Drug Administration Center for Drug Evaluation and Research. The report stated that the Onpattro review document highlighted greater risk with respect to certain trials of Alnylam’s Onpattro (patisiran) lipid complex injection, demonstrated “a limited market opportunity in TTRcardiomyopathy,” and constituted “a potential platform safety risk.”

On this news, the Company’s stock price fell from $100.35 per share on September 11, 2018 to $94.75 per share on September 12, 2018—a $5.60 or 5.68% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Alnylam Pharmaceuticals, Inc. (ALNY)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 09/14/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.